AVDL - Avadel Pharmaceuticals estimates Q4 net product revenue of ~$19M
2024-01-08 13:31:27 ET
More on Avadel Pharmaceuticals
- Avadel: Lumryz Lights Up The Oxybate Market, Maintaining Buy Rating
- Assessing Avadel's Lumryz: Clinical Innovation Versus Economic Realities
- Avadel Pharmaceuticals PLC (AVDL) Q3 2023 Earnings Call Transcript
- UBS lowers Jazz to neutral, cites potential competition from Avadel drug
- Seeking Alpha’s Quant Rating on Avadel Pharmaceuticals
For further details see:
Avadel Pharmaceuticals estimates Q4 net product revenue of ~$19M